Voyager Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Voyager Therapeutics, Inc. (VYGR) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $2.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-06
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $2.43M, a 41.13% decline year-over-year.
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $2.49M, a 32.26% decline year-over-year.
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $3.46M, a 3.13% increase year-over-year.
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $4.13M, a 4.40% increase year-over-year.
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $14.79M, a 2.25% increase from fiscal 2024.
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $14.46M, a 33.08% increase from fiscal 2023.
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $10.87M, a 18.73% increase from fiscal 2022.
- Voyager Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $9.15M, a 16.72% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.43M 10-Q · filed 2026-08-06 | $4.92M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.49M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $14.79M 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $3.46M 10-Q · filed 2025-11-10 | $7.59M derived: sum of 2 quarters · filed 2026-08-06 | $11.27M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $4.13M 10-Q · filed 2026-08-06 | $7.81M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.67M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $14.46M 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $3.35M 10-Q · filed 2025-11-10 | $7.31M derived: sum of 2 quarters · filed 2025-11-10 | $10.81M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $3.96M 10-Q · filed 2025-11-10 | $7.46M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $3.50M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $10.87M 10-K · filed 2026-03-09 | |||
| 2023-09-30 | $2.79M 10-Q · filed 2024-11-12 | $5.42M derived: sum of 2 quarters · filed 2024-11-12 | $7.93M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.63M 10-Q · filed 2024-11-12 | $5.13M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $2.50M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $9.15M 10-K · filed 2025-03-11 | |||
| 2022-09-30 | $2.11M 10-Q · filed 2023-11-06 | $4.57M derived: sum of 2 quarters · filed 2023-11-06 | $6.83M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $2.46M 10-Q · filed 2023-11-06 | $4.73M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $2.27M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $10.99M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $2.02M 10-Q · filed 2022-11-08 | $5.90M derived: sum of 2 quarters · filed 2022-11-08 | $9.39M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.87M 10-Q · filed 2022-11-08 | $7.37M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $3.50M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $14.50M 10-K · filed 2023-03-07 | |||
| 2020-09-30 | $3.44M 10-Q · filed 2021-11-02 | $7.23M derived: sum of 2 quarters · filed 2021-11-02 | $11.18M derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $3.79M 10-Q · filed 2021-11-02 | $7.74M derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $3.95M 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $15.64M 10-K · filed 2022-03-08 | |||
| 2019-09-30 | $3.27M 10-Q · filed 2020-11-09 | $8.46M derived: sum of 2 quarters · filed 2020-11-09 | $11.92M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $5.20M 10-Q · filed 2020-11-09 | $8.65M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $3.46M 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $15.71M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $2.58M 10-Q · filed 2019-11-06 | $10.65M derived: sum of 2 quarters · filed 2019-11-06 | $12.91M derived: sum of 3 quarters · filed 2019-11-06 | |
| 2018-06-30 | $8.06M 10-Q · filed 2019-11-06 | $10.32M derived: sum of 2 quarters · filed 2019-11-06 | ||
| 2018-03-31 | $2.26M 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $9.13M 10-K · filed 2020-03-03 | |||
| 2016-12-31 | $6.31M 10-K · filed 2019-02-26 | |||
| 2015-12-31 | $4.03M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |